Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti; Gunar Günther; Claude Leu; Daniela Cirillo; Raquel Duarte; Alberto L Garcia-Basteiro; Delia Goletti; Mateja Jankovic; Liga Kuksa; Florian P Maurer; Frédéric Méchaï; Simon Tiberi; Frank van Leth; Nicolas Veziris; Christoph Lange; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet)

doi:10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Eur Respir J. 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022. Print 2022 May.

Authors

Lorenzo Guglielmetti^{1

2

3}, Gunar Günther^{4

5}, Claude Leu⁴, Daniela Cirillo⁶, Raquel Duarte^{7

8

9

10}, Alberto L Garcia-Basteiro^{11

12}, Delia Goletti¹³, Mateja Jankovic¹⁴, Liga Kuksa^{15

16}, Florian P Maurer^{17

18

19}, Frédéric Méchaï²⁰, Simon Tiberi^{21

22}, Frank van Leth^{23

24}, Nicolas Veziris^{2

25

26}, Christoph Lange^{19

27

28

29}; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet)

Affiliations

¹ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France lorenzo.guglielmetti@aphp.fr.
² APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.
³ APHP, Infectious Disease Unit, Avicenne Hospital, Bobigny, France.
⁴ Department of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁵ Department of Internal Medicine, School of Medicine, University of Namibia, Windhoek, Namibia.
⁶ WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milano, Italy.
⁷ Epidemiology Research Unit (EpiUnit), Institute of Public Health, University of Porto, Porto, Portugal.
⁸ Departamento de Ciências de Saúde Pública, Ciências Forenses e Educação Médica, Faculty of Medicine, University of Porto, Porto, Portugal.
⁹ Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
¹⁰ National Tuberculosis Program, Directorate-General of Health, Lisbon, Portugal.
¹¹ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Moçambique.
¹² ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
¹³ National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.
¹⁴ Clinic for Lung Diseases, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia.
¹⁵ Riga East University Hospital, TB and Lung Disease Centre, Riga, Latvia.
¹⁶ Riga Stradins University, Riga, Latvia.
¹⁷ National and Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany.
¹⁸ Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁹ German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
²⁰ APHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France.
²¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
²² Royal London Hospital, Barts Health National Health Service Trust, London, UK.
²³ VU University, Department of Health Sciences, Amsterdam, The Netherlands.
²⁴ Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
²⁵ APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine, Département de bactériologie, Paris, France.
²⁶ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France.
²⁷ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
²⁸ Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
²⁹ Baylor College of Medicine and Texas Childreńs Hospital, Global TB Program, Houston, TX, USA.

Abstract

Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibiotics, Antitubercular* / therapeutic use
Antitubercular Agents / therapeutic use
Drug Therapy, Combination
Europe
Humans
Rifampin / analogs & derivatives
Rifampin / therapeutic use
Tuberculosis* / drug therapy
Tuberculosis* / epidemiology

Substances

Antibiotics, Antitubercular
Antitubercular Agents
Rifampin
rifapentine